<DOC>
	<DOCNO>NCT01387503</DOCNO>
	<brief_summary>This clinical trial aim extend chance liver transplantation , downstaging procedure , patient hepatocellular carcinoma ( HCC ) exceed conventional Milan Criteria . Those patient achieve sustain tumor response downstaging randomize either undergo liver transplantation proceed conventional non-transplant treatment . The aim study demonstrate unequivocally liver transplantation may provide survival benefit , acceptable survival rate least 60 % 5 year , patient demonstrate radiological sustain tumor response downstaging . Noteworthy response chosen rather stage migration endpoint downstaging .</brief_summary>
	<brief_title>Expansion Conventional Criteria Liver Transplantation Hepatocellular Carcinoma Through Downstaging</brief_title>
	<detailed_description>1 . Downstaging phase Patients consider eligible study undergo downstaging procedure accord stage disease Center 's policy . Length intensity downstaging center specific centrally pre-determined , inferior 18 month . Downstaging procedure stop , accord Investigators ' judgement , best possible tumor response achieve : timepoint radiological evaluation tumor response accord modify RECIST ( mRECIST ) criterion perform . Patients achieve Complete Partial Response ( PR CR ) proceed Bridging Phase , Stable Progressive disease ( SD PD ) drop-out study . 2 . Bridging phase Patients achieve PR CR downstaging receive systemic therapy sorafenib three month . After three month radiological response assess accord mRECIST criterion . If sustain response demonstrate patient proceed randomization . PD bridge phase cause drop-out study . 3 . Randomization study period Patients randomize 1:1 ratio , use computer generate list stratified Center compliance sorafenib treatment ( base whether ≤50 % &gt; 50 % standard dosage ( 800 mg/day ) administer ) . 1 . The experimental group ( Group 1 - transplant strategy ) enlist transplantation undergo liver transplantation within 8 month unless major medical oncological contraindication occur . 2 . The control group ( Group 2 - non-transplant strategy ) continue sorafenib progression . Then may treat either medical locoregional/surgical therapy accord best practice Centers ' policy , exclude transplantation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Patient 's age ≥ 18 yr ≤ 65 yr Presence cirrhosis etiology ChildPugh class ≤ B7 ECOG Performance Status ≤ 1 Diagnosis HCC either biopsy accord AASLD criterion HCC exceed Milan Criteria 5yr estimate survival transplantation &gt; 50 % accord Metroticket calculator ( http : //www.hccoltmetroticket.org/calculator ) Women child bear potential negative serum pregnancy test perform enrolment Absence general contraindication sorafenib/molecular targeted therapy Presence extrahepatic tumor spread Presence macrovascular invasion Sorafenib therapy start &gt; 2 month enrolment Concurrent cancer , distinct HCC ( except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ) Previous history cancer , even curatively treat , &lt; 5 year prior entry Active intravenous alcohol abuser HIV infection History serious cardiac disease Severe pulmonary hypertension treatable medical therapy Patients life expectancy le 3 month due HCC le 6 month due disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Downstaging</keyword>
	<keyword>Trans-arterial chemoembolization ( TACE )</keyword>
	<keyword>Radiofrequency ablation ( RFA )</keyword>
	<keyword>Liver resection</keyword>
	<keyword>Sorafenib</keyword>
</DOC>